The Liver Meeting, hosted by the American Association for the Study of Liver Diseases, recently provided updates on the latest advancements in liver health. One of the key highlights was the presentation of new data on the MASH drug resmetirom, known by its brand name Rezdiffra.
Rezdiffra, a daily pill developed by Madrigal, received accelerated FDA approval last year. While the drug has shown promise in treating liver-related conditions, such as improving MELD scores and reducing liver-related mortality, more detailed outcomes from the MAESTRO-NASH OUTCOMES trial are expected in 2027. The presentation emphasized the importance of consistent treatment for MASH patients to maximize the benefits of the drug.
Unfortunately, access to the full article is restricted to STAT+ subscribers. For exclusive access to in-depth analysis, newsletters, premium events, and news alerts, readers are encouraged to subscribe to STAT+. This subscription service provides valuable insights and updates on the latest developments in liver research and treatment.
Stay informed about the latest advancements in liver health by subscribing to STAT+ and unlocking exclusive content on liver diseases and treatments. Don’t miss out on the opportunity to access premium articles and stay updated on the promises and pitfalls of liver disease treatment. Subscribe now to stay ahead in the field of liver health research and treatment.
